Chemomab Says It Presented Two Scientific Posters Supporting The Clinical Rationale For Company's Primary Sclerosing Cholangitis Program At EASL 2024, For The Study Of Liver
Chemomab Says It Presented Two Scientific Posters Supporting The Clinical Rationale For Company's Primary Sclerosing Cholangitis Program At EASL 2024, For The Study Of Liver
Chemomab表示，它在EASL 2024中展示了兩張科學海報，支持了公司原發性硬化性膽管炎計劃的臨床基礎，用於肝臟研究。
Chemomab Says It Presented Two Scientific Posters Supporting The Clinical Rationale For Company's Primary Sclerosing Cholangitis Program At EASL 2024, For The Study Of Liver
Chemomab表示，它在EASL 2024中展示了兩張科學海報，支持了公司原發性硬化性膽管炎計劃的臨床基礎，用於肝臟研究。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。